Clinical trial register · Spain

Clinical Trials in Granada, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC

5875

Studies in scope

all four open statuses

3096

Recruiting now

open to new participants

1137

Lead sponsors

across recruiting studies

Top sites

Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746

Trials with a site in Granada

Status

Study

Lead sponsor

Phase

Enrol

Sites in Spain

Start

Not yet open

A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

NCT07861100Cardiovascular Risk, Obesity

DrugZenagamtide

Novo Nordisk A/S

Phase 3

8,500

Marbella, A Coruña, Barcelona, Boadilla del Monte, Cáceres, Córdoba, El Palmar, Granada

2026-10-26

Not yet open

Effects of a Community-based Multicomponent Physical Exercise Program on Physical Function, Frailty, and Sarcopenia in Older Adults From the Municipality of Santoña: a Quasi-experimental Study.

NCT07732478Frailty/Sarcopenia, Frailty in Older Adults, Sarcopenia

Universidad de Granada

Not applicable

300

Granada

2026-10-01

Recruiting

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

NCT07701941Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer

DrugsPatritumab deruxtecan·Trastuzumab deruxtecan

Daiichi Sankyo

Phase 1/2

220

Badalona, Barcelona, Granada, Madrid, Málaga, Pamplona, Pozuelo de Alarcón, Santa Cruz de Tenerife

2026-09-17

Not yet open

Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)

NCT07247786Non Small Cell Lung Cancer, Respiratory Tract Neoplasm

DrugsFecal Microbiota Transplantation·Durvalumab·Paclitaxel·Carboplatin

Fundación GECP

Phase 2

Alicante, Elche, Badalona, Barcelona, L'Hospitalet de Llobregat, Granada, Santiago de Compostela, Lugo

2026-09-15

Not yet open

Predictive Score in Patients With Hematological Malignancies Colonized by Multidrug-resistant Enterobacteriaceae

NCT07396571Hemato-oncologic Patients, Colonization, Neutropenia, Enterobacteria Non Susceptible to Carbapenem Carrier

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Observational

535

Almería, Jerez de la Frontera, Vigo, Pamplona, Barcelona, Cadiz, Granada, Huelva

2026-09-04

Not yet open

Preventing Breast Cancer Therapy-related Cardiovascular Toxicity With a Daily-adapted Program With Mhealth Support

NCT06518200Breast Cancer Female

Universidad de Granada

Not applicable

102

Granada

2026-09-01

Recruiting

Pelvic Floor Muscle Training and Neuromuscular Performance in Women's Rugby

NCT07757633Urinary Incontinence (UI), Pelvic Floor Disorders

Universidad de Granada

Not applicable

Granada

2026-09

Not yet open

Reducing the Time Interval for Implant Placement After Extraction Socket Preservation Using BIOTECK Materials and OITECH Implant System

NCT07746869Alveolar Bone Resorption

Bioteck S.p.A.

Observational

Granada

2026-09

Recruiting

Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

1,072

Barcelona, Castellon, Granada, Las Palmas de Gran Canaria, Madrid, Valencia, Vigo

2026-08-31

Recruiting

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

NCT07794579Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal

DrugOrforglipron

Eli Lilly and Company

Phase 3

2,001

Alcobendas, Barcelona, Centelles, Ferrol, Granada, Madrid, Pozuelo de Alarcón, Seville

2026-08-26

Recruiting

A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

NCT07753993Chronic Kidney Disease

DrugElecoglipron

AstraZeneca

Phase 3

7,000

Badajoz, Barcelona, Burgos, Córdoba, Granada, Madrid, Majadahonda, Málaga

2026-08-21

Recruiting

Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease

NCT07348640Steno-occlusive Disease

DrugsGadopiclenol·Gadoterate meglumine

Guerbet

Phase 3

315

Barcelona, Granada, Madrid

2026-07-28

Recruiting

Impact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4/6 Inhibitors

NCT07215364Early-stage Breast Cancer

Spanish Breast Cancer Research Group

Not applicable

L'Hospitalet de Llobregat, Pamplona, Granada, Madrid, Seville

2026-07-02

Not yet open

TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma

NCT07507968Esophagogastric Adenocarcinoma

DrugDurvalumab

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2

101

Badalona, Barcelona, Granada, Jaén, Málaga, Oviedo, Pamplona, Valencia

2026-07-01

Not yet open

Optimizing the Use of Aspirin for the Prevention of Preeclampsia

NCT07665853Preeclampsia

Hospital Universitari Vall d'Hebron Research Institute

Phase 3

15,160

Granada, Barcelona, Girona, Tarragona, Barakaldo, A Coruña, Alicante, Burgos

2026-07-01

Not yet open

Efficacy of a Multimodal Physiotherapy Program and Mobile-App Guided Meditation in Adults With Frequent or Chronic Tension-Type Headache

NCT07240532Tension-Type Headache, Chronic Tension-type Headache, Frequent Episodic Tension-Type Headache

Universidad de Granada

Not applicable

Granada

2026-07

Recruiting

Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests

NCT07106632Early Breast Cancer, Premenopausal Breast Cancer, HR+/HER2- Breast Cancer

UNICANCER

Phase 3

3,380

Alicante, Barcelona, Castillón, Granada, Madrid, Manresa, Palma, Seville

2026-06-26

Recruiting

Safety and Performances of the LINEA Cardiac Pacing Lead Optimized for the Implantation in Interventricular Septum

NCT07342608Bradycardia, Left Bundle Branch Area Pacing, Left Bundle Branch Pacing

MicroPort CRM

Not applicable

450

Girona, Granada, Valencia

2026-06-23

Recruiting

A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer

NCT07401381Hormone Receptor Positive Early Breast Cancer

Rovi Pharmaceuticals Laboratories

Phase 1

120

Alcorcón, Barcelona, Granada, Jaén, León, Lleida, Manresa, Málaga

2026-06-08

Recruiting

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

NCT07333066Metastatic Hormone-sensitive Prostate Cancer

DrugsApalutamide (Erleada)·Docetaxel

Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD

Phase 3

320

Zaragoza, Barcelona, L'Hospitalet de Llobregat, Santander, Granada, Santiago de Compostela, Madrid, Murcia

2026-06-05

Recruiting

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

NCT07024706Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

DrugsVenclyxto·Acalabrutinib·Venclexta·Venetoclax

AstraZeneca

Phase 2

Barcelona, Granada, Madrid, Majadahonda

2026-06-04

Not yet open

Adjuvant Clopidogrel in Staphylococcus Aureus Bacteremia

NCT07384702Bacteremia Due to Staphylococcus Aureus

DrugClopidogrel

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase 2

230

Alicante, Barcelona, Córdoba, Granada, Jerez de la Frontera, Madrid, Palma de Mallorca, Seville

2026-06

Not yet open

Masitinib in Patients With Mild Alzheimer's Disease

NCT05564169Alzheimer Disease

DrugMasitinib

AB Science

Phase 3

600

Albacete, Barcelona, Donostia / San Sebastian, Granada, Madrid, Murcia, Pamplona, Zamora

2026-06

Recruiting

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

NCT07492641HR+/HER2- Breast Cancer

DrugsBGB-43395·Abemaciclib·Ribociclib·Palbociclib

BeOne Medicines

Phase 3

1,056

Elcheelx, Granada, Madrid, Santiago de Compostela, Seville

2026-05-22

Recruiting

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

NCT07413939HER2-positive Breast Cancer

DrugsZN-A-1041·Tucatinib·Trastuzumab·Capecitabine

Hoffmann-La Roche

Phase 2/3

650

EL Palmar (EL Palmar), San Cristóbal de La Laguna, Bilbao, Barcelona, Granada, Jaén, Madrid, Málaga

2026-05-21

Recruiting

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)

NCT07545759Irritable Bowel Syndrome, Diarrhea

DrugBrenipatide

Eli Lilly and Company

Phase 2

531

Barcelona, Centelles, Granada, Madrid, Marbella, Salamanca, Santiago de Compostela

2026-05-06

Not yet open

Virtual Exercise Training and Its Impact on Bone Compartments in Adult Survivors of Childhood Cancer

NCT07022262Cancer Survivors

Universidad de Granada

Not applicable

116

Granada

2026-05

Not yet open

Behavioural Intervention to Decrease Exposure to Emerging Chemical Pollutants

NCT07465315Environmental Exposure

Universidad de Granada

Phase 2/3

740

Granada, Motril, Fuenlabrada, Madrid, Melilla

2026-05

Recruiting

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)

NCT07545772Irritable Bowel Syndrome, Constipation

DrugBrenipatide

Eli Lilly and Company

Phase 2

342

Barcelona, Centelles, Granada, Madrid, Marbella, Salamanca, Santiago de Compostela

2026-04-29

Recruiting

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

NCT07405801Breast Cancer

DrugsInavolisib·Ribociclib·Fulvestrant

Hoffmann-La Roche

Phase 2

L'Hospitalet de Llobregat, Barcelona, Granada, Madrid, Valencia

2026-04-07

Recruiting

Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer

NCT07195227Hormon Receptor Positive Breast Cancer, Breast Cancer

DrugsCamizestrant·Ribociclib

MedSIR

Phase 2

150

Alicante, Barcelona, Girona, Granada, Jerez de la Frontera, León, Madrid, Málaga

2026-03-24

Recruiting

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

NCT07355296Proteinuric Kidney Diseases

DrugApecotrep

Boehringer Ingelheim

Phase 2

132

Barcelona, Esplugues de Llobregat, Granada, Madrid, Valencia

2026-03-23

Active, closed

TuJuggling: Comparing Two Juggling Learning Methods in College Students

NCT07528924Motor Skill Learning, Juggling Performance

Universidad de Granada

Not applicable

200

Granada

2026-03-23

Recruiting

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

NCT07475806Muscle-invasive Bladder Cancer

DrugsEnfortumab Vedotin·Pembrolizumab

Astellas Pharma Global Development, Inc.

Phase 2

240

Granada, Ourense

2026-03-12

Recruiting

Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome

NCT07476859Acute Coronary Syndromes (ACS), Iron Deficiencies, Elderly (People Aged 65 or More)

DrugsFerinject·Ferric Carboxymaltose

Fundación para la Investigación del Hospital Clínico de Valencia

Phase 4

538

El Palmar, Vigo, Badajoz, Barcelona, Granada, León, Madrid, Pamplona

2026-03-05

Recruiting

Saffron Extract Supplementation and Sleep Quality in Middle-Aged Adults

NCT07497698Sleep

Universidad de Granada

Not applicable

Granada

2026-03-01

Recruiting

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

NCT07368998Breast Cancer

DrugsInavolisib·Fulvestrant

Hoffmann-La Roche

Phase 2

Barcelona, Granada, Madrid, Valencia

2026-02-18

Recruiting

Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

NCT07371585Breast Cancer Stage IV

DrugsPertuzumab·Trastuzumab deruxtecan

SOLTI Breast Cancer Research Group

Phase 2

300

Barcelona, A Coruña, Alicante, Badajoz, Bilbao, Girona, Granada, L'Hospitalet de Llobregat

2026-02-18

Recruiting

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

NCT07220083Focal Segmental Glomerulosclerosis

DrugApecotrep

Boehringer Ingelheim

Phase 3

286

Almería, Barcelona, Granada, Madrid

2026-02-16

Recruiting

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

NCT07202546HIV Infections

DrugsVH4524184·Dovato·Dolutegravir/Lamivudine

ViiV Healthcare

Phase 2

186

A Coruña, Alicante, Almería, Badalona, Barcelona, Elche Alicante, Getafe, Granada

2026-02-11

Recruiting

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

NCT07258511Multiple Myeloma

DrugsRamantamig·Teclistamab

Janssen Research & Development, LLC

Phase 3

400

Badalona, Barcelona, Granada, Madrid, Pozuelo de Alarcón, Salamanca, Usansolo, Valencia

2026-02-04

Active, closed

Effects of Functional Task Training on Muscle Health and Function in Older Adults With Sarcopenia

NCT07494916Sarcopenia, Aging, Physical Functional Performance, Muscle Weakness | Patient

Universidad de Granada

Not applicable

Granada

2026-02-02

Not yet open

Yttrium-90 Radioembolization Neoadjuvant Therapy With Immune Marker Profiling and Dosimetry for Potentially Resectable Patients With Colorectal Liver Metastases

NCT07406126Colorectal Liver Metastases (CRCLM), Unresectable Colorectal Liver Metastases

Fernando Gómez Muñoz

Observational

Pamplona, Castelló, Granada, Madrid, Valencia

2026-02

Recruiting

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer

DrugsSigvotatug vedotin·PF-08634404

Pfizer

Phase 1/2

162

Jaén, Barcelona, Jerez de la Frontera, Madrid, Málaga, Valencia, Cadiz, Granada

2026-01-30

Recruiting

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

NCT07277231Chronic Lymphocytic Leukemia

DrugsSonrotoclax·Venclyxto·Acalabrutinib·Venclexta

BeOne Medicines

Phase 3

500

Granada, Madrid, Majadahonda, Murcia

2026-01-22

Recruiting

Withdrawal of Heart Failure Treatment Patients With Non-ischemic Cardiomyopathy Who Have Been Super-responders to Cardiac Resynchronization Therapy.

NCT07851779Non-ischemic Cardiomyopathy, Cardiac Resynchronisation Therapy (CRT)

Institut d'Investigació Biomèdica de Bellvitge

Phase 4

L'Hospitalet de Llobregat, Barcelona, Girona, Granada

2026-01-14

Recruiting

A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

NCT06931717Non-Small Cell Lung Cancer

DrugCemiplimab

ETOP IBCSG Partners Foundation

Phase 3

390

A Coruña, Alicante, Barakaldo, Barcelona, Granada, Jerez de la Frontera, Madrid, Santa Cruz de Tenerife

2026-01-12

By invitation

Lead Evaluation for Defibrillation and Reliability Post Approval Study

NCT07005232Tachyarrhythmia

Medtronic

Observational

2,000

Granada, A Coruña, Madrid, Santa Cruz de Tenerife, Valencia

2026-01-07

Recruiting

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsPF-08634404·Pembrolizumab

Pfizer

Phase 3

1,410

Santiago de Compostela, Elche, Granada, Seville, Barcelona, L'Hospitalet de Llobregat, Jerez de la Frontera, Girona

2026-01-06

Recruiting

Comparison of Bone-patellar Tendon-bone and Patellar Tendon-bone Grafts in ACL Reconstruction

NCT07475351Anterior Cruciate Ligament (ACL) Reconstruction, Anterior Cruciate Ligament Injury

Universidad de Granada

Not applicable

110

Granada

2026-01-01

Recruiting

LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome

NCT07234695Down Syndrome, Down Syndrome (DS), Down Syndrome (Trisomy 21), Alzheimer Dementia

DrugLevetiracetam

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Phase 3

120

Granada, Donostia / San Sebastian, Santander, Barcelona, Madrid

2025-12-22

Recruiting

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

NCT07174336Breast Neoplasms, Neoplasm Metastasis

DrugsTersolisib·Exemestane·Anastrozole·Abemaciclib

Eli Lilly and Company

Phase 3

800

Badajoz, Barcelona, Cáceres, Donostia / San Sebastian, Granada, Hospitalet, Jaén, Las Palmas de Gran Canaria

2025-12-22

Active, closed

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

NCT07128199Lung Cancer, Adjuvant, Post-surgical, EGFR

DrugZipalertinib

Taiho Oncology, Inc.

Phase 3

360

Palma de Mallorca, Badalona, Barcelona, Sabadell, Granada, Las Palmas de Gran Canaria, Lugo, Madrid

2025-12-22

Recruiting

Safety, Performance, and Clinical Benefit of Pacing the Left Bundle Branch Area - Post-Market Clinical Follow-up

NCT07209852Bradycardia, Atrioventricular Block, Sinus Node Dysfunction, Bundle-Branch Block

Boston Scientific Corporation

Observational

140

Granada, Zaragoza

2025-12-19

Recruiting

Tuvusertib in Astrocytoma With ATRX Mutation

NCT07417761Astrocytoma

DrugTuvusertib

Grupo Español de Investigación en Neurooncología

Phase 2

Palma de Mallorca, Barcelona, Barakaldo, Granada, Madrid, Vigo, Salamanca, Seville

2025-12-19

Recruiting

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

NCT07237256Breast Cancer

UNICANCER

Phase 3

3,902

Badajoz, Barcelona, Bilbao, Fuenlabrada, Granada, Jaén, Jerez de la Frontera, L'Hospitalet de Llobregat

2025-12-18

Recruiting

Time-Restricted Eating as a Potential Strategy to Promote Weight Loss Maintenance in Patients With Obesity

NCT07315659Obesity

Universidad de Granada

Not applicable

212

Granada

2025-12-18

Recruiting

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

DrugsAbiraterone·Enzalutamide

Novartis Pharmaceuticals

Phase 1/2

123

Granada, L'Hospitalet de Llobregat, Barcelona, Madrid

2025-12-05

Active, closed

Epidemiology of Narcolepsy Type 1 and Type 2 in Spain

NCT07299097Narcolepsy Type 1, Narcolepsy Type 2

Takeda

Observational

402

Castellon, Pamplona, Alzira, Barcelona, Granada, Madrid, Seville, Vitoria-Gasteiz

2025-12-02

Recruiting

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

NCT07228832Metastatic Colorectal Cancer (CRC)

DrugsIvonescimab·Leucovorin·Adrucil·Oxaliplatin

Summit Therapeutics

Phase 3

600

A Coruña, Barcelona, Córdoba, Granada, Madrid, Málaga, Palma de Mallorca, Santander

2025-11-18

Recruiting

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT07219420Palmoplantar Pustulosis

DrugBimekizumab

UCB Biopharma SRL

Phase 3

320

Alicante, Badalona, Granada, Madrid, Manises, Málaga, Santiago de Compostela, Valencia

2025-11-14

Active, closed

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

NCT07228390Hidradenitis Suppurativa

DrugRitlecitinib

Pfizer

Phase 2

128

Manises, Cadiz, Granada, Madrid, Pontevedra

2025-11-13

Recruiting

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

NCT07170917Hidradenitis Suppurativa

DrugBrivekimig

Sanofi

Phase 2

208

Santiago de Compostela, Las Palmas de Gran Canaria, Manises, Cadiz, Granada, Madrid

2025-11-06

Recruiting

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer

DrugsPalazestrant·Ribociclib·Letrozole

Olema Pharmaceuticals, Inc.

Phase 3

1,000

Alicante, Barcelona, Granada, León, Lleida, Madrid, Murcia, Seville

2025-11-03

Active, closed

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

NCT07287644Hidradenitis Suppurativa (HS)

DrugBFB759

Bluefin Biomedicine, Inc.

Phase 2/3

210

Granada, Granollers, Las Palmas de Gran Canaria, Madrid, Pontevedra, Valencia

2025-11-03

Recruiting

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

NCT07205822Breast Cancer

DrugDato-DXd

AstraZeneca

Phase 3

100

A Coruña, Barcelona, Granada, Madrid, Seville, Valencia

2025-10-30

Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis

DrugsSofe-M·MIRV·Pegylated liposomal doxorubicin·Topotecan

Eli Lilly and Company

Phase 3

1,630

Barcelona, Castellon, Granada, Madrid, Málaga, San Sebastián de los Reyes, Santiago de Compostela, Toledo

2025-10-22

Recruiting

Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

NCT07407465Colorectal Cancer, Colorectal Adenocarcinoma, Rectal Adenocarcinoma, Rectal Cancer, Adenocarcinoma

DrugsTrastuzumab deruxtecan·Capecitabine·Bevacizumab

Gruppo Oncologico del Nord-Ovest

Phase 2

Barcelona, Granada, Madrid, Santiago de Compostela, Valencia

2025-10-20

By invitation

A Physical Activity Program for People With Heart Failure

NCT07204834Heart Failure

Universidad de Granada

Not applicable

200

Granada, Motril

2025-10-08

Recruiting

Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

NCT07389265Metastatic Colorectal Cancer (mCRC)

DrugsFOLFOX (Folinic acid·Erbitux·Folfox·Fluorouracil

University of Campania Luigi Vanvitelli

Phase 3

480

Barcelona, Cartagena, Córdoba, Granada, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona

2025-10-01

Recruiting

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma

DrugsPF-08046054·Docetaxel

Pfizer

Phase 3

680

A Coruña, Badalona, Barcelona, Madrid, Badajoz, Granada, Palma, Seville

2025-09-29

Recruiting

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

NCT07102381HER2-positive Breast Cancer, Breast Cancer

DrugsZanidatamab·Pertuzumab·Trastuzumab·Docetaxel

Jazz Pharmaceuticals

Phase 2

125

Granada, Vigo, Barcelona, Madrid

2025-09-24

Recruiting

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)

Eli Lilly and Company

Phase 3

10,450

A Coruña, Barcelona, Centelles, Córdoba, Ferrol, Granada, Huelva, Jaén

2025-09-02

Not yet open

Short- and Long-Term Effects of Whole-Body Photobiomodulation in Type II Diabetes Patients: A Protocol for a Controlled Clinical Trial

NCT07047248Type II Diabetes Mellitus

University of Malaga

Not applicable

Granada

2025-08-30

Recruiting

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965Breast Cancer

DrugsPrifetrastat·Exemestane·Everolimus·Fulvestrant

Pfizer

Phase 3

400

A Coruña, Barcelona, Bilbao, Málaga, Granada, Jaén, Zaragoza

2025-08-05

Recruiting

Permanent Conduction System Pacing Versus Atrioventricular Management for Patients With Wide QRS and Patent AV Conduction

NCT07585799Bradycardia

Óscar Cano Pérez

Not applicable

120

Granada, Zaragoza, Valencia

2025-07-29

Recruiting

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

NCT06911502Follicular Lymphoma

DrugsPrednisone/Prednisolone·Golcadomide·Bendamustine·Vincristine

Celgene

Phase 3

400

Sabadell, Santander, Madrid, Valencia, Granada

2025-07-28

Recruiting

Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response

NCT07582887Breast Cancer, Metastatic Breast Cancer, Drug-Related Side Effects and Adverse Reactions, Pharmacogenetic Variant

DrugsDato-DXd·Sacituzumab Govitecan·Trastuzumab deruxtecan

Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental

Observational

Granada

2025-07-15

Recruiting

Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)

NCT07153445Non Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer

DrugsTecentriq·Paraplatin·Taxol·Atezolizumab

Fundación GECP

Phase 2

Alicante, Badalona, Barcelona, Bilbao, Jerez de la Frontera, Girona, Granada, A Coruña

2025-07-08

Active, closed

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT07047118Prostatic Cancer, Castration-Resistant

DrugsLuxdegalutamide·Lu-PSMA

Novartis Pharmaceuticals

Phase 2

138

Granada, El Palmar, Barcelona, Seville

2025-07-03

Recruiting

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

NCT07177352Alzheimers Disease

Hoffmann-La Roche

Phase 3

80,000

Denia, Martorell, Terrassa, Pozuelo de Alarcón, Barcelona, Córdoba, Donosti-San Sebastián, Granada

2025-07-02

Active, closed

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

NCT06981078Chronic Obstructive Pulmonary Disease

DrugVerekitug

Upstream Bio Inc.

Phase 2

666

Palma de Mallorca, Torrelavega, Jerez de la Frontera, Cáceres, Granada, Madrid, Pozuelo de Alarcón, Benalmádena

2025-07-02

Recruiting

Thyroidectomy for Graves' Disease or Amiodarone-induced Thyrotoxicosis

NCT06963203Graves Disease, Amiodarone-Induced Thyrotoxicosis, Thyroidectomy

Andrea Goldmann

Observational

486

Granada, Marbella

2025-07-01

Recruiting

A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

NCT06979375Heart Failure

DrugCDR132L

Novo Nordisk A/S

Phase 2

200

Granada, Girona, El Palmar, Barcelona, Denia, Las Palmas de Gran Canaria, Madrid, Majadahonda

2025-06-30

Recruiting

Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

NCT06486883Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma

DrugsCDK4/6i·Trastuzumab deruxtecan

MedSIR

Phase 2

200

Barcelona, Cáceres, Girona, Granada, Jaén, Madrid, Majadahonda, Murcia

2025-06-30

Active, closed

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

NCT06966453Breast Cancer, Breast Neoplasms

DrugDisitamab Vedotin

Pfizer

Phase 1/2

Barcelona, Madrid, Málaga, Valencia, Granada

2025-06-30

By invitation

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07007637Hidradenitis Suppurativa

DrugSonelokimab

MoonLake Immunotherapeutics AG

Phase 3

835

Alicante, Badalona, Barcelona, Cadiz, Córdoba, Granada, Granollers, Madrid

2025-06-27

Recruiting

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

NCT06979362Heart Failure

DrugCDR132L

Novo Nordisk A/S

Phase 2

200

Granada, El Palmar, Barcelona, Las Palmas de Gran Canaria, Madrid, Valencia

2025-06-27

Recruiting

PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

NCT06409936CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia, BCR/ABL-Positive, Chronic Myeloid Leukemia

DrugsAsciminib·Nilotinib

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2

160

Barcelona, Bilbao, Girona, Granada, Las Palmas de Gran Canaria, Madrid, Murcia, Salamanca

2025-06-26

Recruiting

Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

NCT06856213Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

DrugsCetuximab·Paclitaxel

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Phase 2

Santiago de Compostela, Badalona, Barcelona, Santander, Granada, A Coruña, Lugo, Madrid

2025-06-18

Active, closed

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

NCT06832618Atopic Dermatitis

DrugRuxolitinib

Incyte Corporation

Phase 3

159

Alicante, Barcelona, Esplugues de Llobregat, Granada, Madrid, Manises, Málaga, Santiago de Compostela

2025-06-17

Active, closed

Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study

NCT06958315Atherosclerotic Vascular Disease, Heterozygous Familial Hypercholesterolemia

Novartis Pharmaceuticals

Observational

219

Cadiz, Granada, Huelva, Jaén, Marbella, Mallorca, Puerto Real, Santander

2025-06-16

Recruiting

Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

NCT06878664Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)

DrugsAmino acid·Lanreotide·Octreotide LAR·Lutathera

Grupo Espanol de Tumores Neuroendocrinos

Phase 3

166

Barcelona, L'Hospitalet de Llobregat, Burgos, Granada, Madrid, Oviedo, Seville, Valencia

2025-06-12

Active, closed

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

NCT06958211Hidradenitis Suppurativa

DrugRuxolitinib

Incyte Corporation

Phase 3

573

Barcelona, Esplugues de Llobregat, Granada, Granollers, Las Palmas de Gran Canaria, Madrid, Manises, Santiago de Compostela

2025-06-12

Active, closed

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

NCT06956235Hidradenitis Suppurativa

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 2

149

Manises, Barcelona, Granada

2025-06-09

Recruiting

ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT06902558Autosomal Dominant Polycystic Kidney Disease

Calico Life Sciences LLC

Phase 2

240

Barcelona, L'Hospitalet de Llobregat, Granada, Madrid, Seville, Valencia

2025-06-09

Active, closed

A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

NCT06821542Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 3

Badalona, Barcelona, El Palmar, Esplugues de Llobregat, Granada, Las Palmas de Gran Canaria, Madrid, Málaga

2025-06-04

Recruiting

Multicenter Study on the Development of Pulmonary Arterial Hypertension Screening Models Based on Artificial Intelligence for Patients With Systemic Sclerosis

NCT07236970Pulmonary Hypertension, Systemic Sclerosis (SSc), Systemic Sclerosis-Associated PAH

Alejandro Cruz Utrilla

Observational

350

Granada, Santander, Barcelona, Madrid

2025-05-30

Recruiting

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

NCT06830798Delayed Graft Function, DGF, Kidney Transplant

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

450

Badajoz, Barakaldo, Barcelona, Cadiz, Córdoba, Granada, Madrid, Málaga

2025-05-19

Recruiting

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

NCT06947993Atopic Dermatitis

Novartis Pharmaceuticals

Phase 2

224

Badalona, Alicante, Granada, Las Palmas GC, Madrid, Pontevedra

2025-05-16

Active, closed

Effectiveness of a Prehabilitation Program for Hip or Knee Arthroplasty Surgery.

NCT06721897Prehabilitation, Knee Osteoarthritis, Hip Osteoarthritis, Physical Therapy Modalities

University of Jaén

Not applicable

Granada

2025-05-15

Recruiting

FB-CT2 Includes Two Prospective, Multi-centre Studies With a Medical Device in Hospital Settings: a Randomized, Dual-arm, Open-label Pilot Study in Spain, Followed by a Single-arm, Non-randomized, Open-label International Pivotal Study

NCT06968364Threatened Preterm Labor

Ultrasound-Innovation Medtech, S.L.

Not applicable

457

A Coruña, Barcelona, Bilbao, Donostia / San Sebastian, Granada, Las Palmas de Gran Canaria, Madrid, Málaga

2025-05-10

Recruiting

Evaluation of Clinical Outcomes of Ponto Procedures Performed in Settings Outside the Main Operating Room (i.e. Out-of-OR)

NCT06930781Hearing Loss, Bone Anchored Hearing Aids

Oticon Medical

Observational

270

Granada

2025-05-07

Recruiting

Optimising TREATment for Severe Gram-Negative Bacterial Infections

NCT07004049Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia, Carbapenem Resistant Bacterial Infection

DrugsCeftolozane-tazobactam·Cefiderocol·Fosfomycin·Meropenem-Vaborbactam

National University of Singapore

Phase 4

600

Alicante, Badajoz, Barakaldo, Barcelona, Córdoba, Granada, Madrid, Málaga

2025-04-21

Recruiting

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)

Avalyn Pharma Inc.

Phase 2

340

Granada, Barcelona, Santander, Madrid, Málaga

2025-04-17

Active, closed

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

NCT06934226Plaque Psoriasis

DrugsIcotrokinra·Ustekinumab

Janssen Research & Development, LLC

Phase 3

752

Alicante, Barakaldo, Barcelona, Granada, Madrid, Manises, Santiago Compostela, Seville

2025-04-15

Active, closed

ASCEND CSP IDE Study

NCT06830746Heart Failure, Ventricular Arrythmia

Abbott Medical Devices

Not applicable

414

Granada, Valencia

2025-04-11

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

NCT06868277Carcinoma, Non-Small Cell Lung

DrugsRilvegostomig·Keytruda·Pembrolizumab

AstraZeneca

Phase 3

830

Badajoz, Badalona, Barcelona, Castellon, Granada, Jaén, Lugo, Madrid

2025-04-10

By invitation

Pain Neuroscience Education, Conditioned Pain Modulation and Emotional Processes in Fibromyalgia

NCT07055971Fibromyalgia

Universidad de Granada

Not applicable

Granada

2025-04-09

Recruiting

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

NCT06750289Eosinophilic Asthma

AstraZeneca

Phase 3

400

Alcorcón, Alzira (Valencia), Badalona, Barakaldo, Barcelona, Burgos, Cáceres, Granada

2025-03-28

Active, closed

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06840392Hidradenitis Suppurativa

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

565

Granada, Palma, Barcelona, Granollers, Las Palmas GC, Madrid, Pontevedra, Seville

2025-03-20

Recruiting

Evaluation of the Nutritional Status of Omega-3 Fatty Acids and the Possible Influences of Dietary Patterns and Different Socioeconomic Factors, in a Spanish Population Over 60 Years of Age

NCT06916455Fatty Acids, Omega-3

Universidad de Granada

Observational

800

Granada

2025-03-19

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

NCT06883305Chronic Obstructive Pulmonary Disease (COPD)

DrugTezepelumab

AstraZeneca

Phase 3

990

Barakaldo, Barcelona, Granada, Madrid, Málaga, Palma de Mallorca, Pamplona, Seville

2025-03-18

Active, closed

A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)

NCT06799520Systemic Lupus Erythematosus (SLE), Alopecia Areata (AA), Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 1

Barcelona, Granada

2025-03-17

Recruiting

Promoting Safe Medication Practices in the Classroom

NCT07389538Self Medication

Universidad de Granada

Not applicable

202

Granada

2025-03-17

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)

DrugsArlo-cel·Carfilzomib·Pomalidomide·Daratumumab

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3

440

Santiago de Compostela, Palma, Badalona, Pamplona, Granada, Salamanca

2025-03-12

Active, closed

Exer-WAPA Project: Physical Exercise on Women's Affective and Physical HeAlth

NCT07466979Psychological Distress, Anxiety Symptoms, Depression Symptoms

Universidad de Granada

Not applicable

100

Granada

2025-03-04

Recruiting

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

NCT06855498Hidradenitis Suppurativa (HS)

DrugPovorcitinib

Incyte Corporation

Phase 3

600

Alcorcón, Alicante, Badalona, Barcelona, Córdoba, Granada, Las Palmas de Gran Canaria, Madrid

2025-02-28

Recruiting

High Intensity Interval Training in the Treatment of Familial Hypercholesterolemia (UPPA-FH)

NCT06833944Familiar Hypercholesterolemia

Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental

Not applicable

Granada

2025-02-20

Recruiting

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

NCT06556563Glioblastoma

DrugsTemozolomide·Keytruda·Pembrolizumab

NovoCure GmbH

Phase 3

741

Madrid, Barcelona, Córdoba, Granada, Seville, Valencia

2025-02-03

Recruiting

Multi-scale Spatio-Temporal Analysis of Research Data

NCT07189312Colorectal Cancer

Universidad de Granada

Observational

Granada

2025-02-02

Recruiting

An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis

NCT06764693Psoriatic Arthritis

AbbVie

Observational

1,200

Málaga, Lorca, Vigo, Seville, Granada, Huelva, Madrid, Murcia

2025-01-31

Active, closed

Adaptation of Human Brown Adipose Tissue to Calorie Restriction

NCT06878989Obesity and Overweight

Universidad de Granada

Not applicable

Granada

2025-01-25

Active, closed

Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer

NCT06612203Advanced Breast Cancer

DrugSacituzumab Govitecan

MedSIR

Phase 1/2

Barcelona, Granada, Madrid, Málaga, Valencia

2025-01-17

Recruiting

Topic Simvastatin for Bone Regeneration

NCT07031778Dimensional Changes, Bone Density

DrugSimvastatin

Universidad de Granada

Early Phase 1

Granada

2025-01-07

Recruiting

Development of a Predictive Model for Sexually Transmitted Infections in Individuals Using Pre-Exposure Prophylaxis for HIV in Spain

NCT06860945Sexually Transmitted Infections (STIs), HIV, PrEP

Hospital Universitario de Valme

Observational

9,000

Almería, Cadiz, Cartagena, Córdoba, Cuenca, Elche, Granada, Huelva

2025-01-01

Recruiting

LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.

NCT06514612Acquired Blepharophimosis

Santen SAS

Phase 3

234

Granada, Madrid, Santiago de Compostela, Zaragoza

2024-12-30

Recruiting

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

NCT06078384Triple-negative Breast Cancer

DrugsTaxol·Keytruda·Paclitaxel·Pembrolizumab

UNICANCER

Phase 2

354

Alicante, Badalona, Barcelona, El Palmar, Granada, L'Hospitalet de Llobregat, León, Lleida

2024-12-27

Recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT06727604Graves' Disease

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

240

Badalona, Barcelona, Córdoba, Granada, Madrid, Pamplona, Seville

2024-12-17

Recruiting

Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.

NCT06724159Genitourinary Cancers

DrugsEnfortumab Vedotin·Darolutamide·Nivolumab

Spanish Oncology Genito-Urinary Group

Observational

500

Albacete, Alicante, Almería, Córdoba, Granada, Jaén, Jerez de la Frontera, Málaga

2024-12-13

Active, closed

A Long-term Safety and Efficacy Study of N-Acetyl-GED-0507-34-LEVO Gel 5%, in Subjects With Acne Vulgaris (GEDACNE-LT)

NCT07389109Acne Vulgaris

PPM Services S.A.

Phase 3

400

Alcorcón, Barcelona, Esplugues de Llobregat, Granada, Madrid, Málaga, Seville, Valencia

2024-12-05

Recruiting

Inhibitory Control Training for Excess Weight: Behavioural, Cognitive and Anthropometric Changes

NCT06600100Overweight and Obesity, Inhibition, Psychological

Raquel Vilar López

Not applicable

Granada

2024-11-30

Recruiting

Inhibitory Control Training and iTBS for Excess Weight: Behavioral and Brain Changes (InhibE).

NCT06668077Overweight and Obesity, Inhibition, Psychological

Raquel Vilar López

Not applicable

141

Granada

2024-11-30

Recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

NCT06369285Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer

DrugAlisertib

Puma Biotechnology, Inc.

Phase 2

225

Alicante, Barakaldo, Barcelona, Bilbao, Cáceres, Granada, Huelva, Jaén

2024-11-19

Recruiting

Virtual Reality Software for Patients With Stroke

NCT06132399Stroke

Universidad de Almeria

Not applicable

Almería, Granada

2024-11-15

Not yet open

Improving Health Status in COVID-19 Long-Hauler

NCT06679218Post COVID-19 Condition

Universidad de Granada

Not applicable

Granada

2024-11-11

Recruiting

Wide-Antral Pulmonary Vein Isolation in Atrial Fibrillation Ablation with a Single-shot Technique (WIDER-PVI)

NCT06698159Atrial Fibrillation, Atrial Fibrillation (Paroxysmal)

Hospital Universitario 12 de Octubre

Not applicable

440

Bilbao, Granada, Huelva, Madrid, Málaga, Seville

2024-11-01

Recruiting

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

NCT05460000Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Clear Cell Carcinoma

North Eastern German Society of Gynaecological Oncology

Phase 2

640

Alicante, Granada, Lugo, Madrid, Manresa, Seville, Tarragona, Valencia

2024-10-11

Recruiting

Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer

NCT06446882HER2-positive Breast Cancer, Early-stage Breast Cancer

Fundacio Clinic Barcelona

Not applicable

304

L'Hospitalet de Llobregat, Granada, Santiago de Compostela, León, Madrid, Murcia, Reus, Bilbao

2024-10-11

Active, closed

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT06388564Chronic Graft-versus-host-disease

DrugsAxatilimab·Ruxolitinib·Methylprednisolone·Prednisolone

Incyte Corporation

Phase 2

130

Barcelona, El Palmar, Granada, Granvia de L'hospitalet 199-203, Madrid, Málaga, Salamanca, Santander

2024-10-11

Active, closed

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

NCT06516965Prurigo Nodularis

DrugPovorcitinib

Incyte Corporation

Phase 3

346

Alicante, Badalona, Barcelona, Córdoba, Granada, Madrid, Majadahonda, Manises

2024-10-10

Recruiting

Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.

NCT06423898Endocarditis, Infective

DrugAmpicillin

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase 4

284

Alava, Barakaldo, Barcelona, Donostia / San Sebastian, Granada, Logroño, Madrid, Málaga

2024-10-09

Recruiting

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06510374Intermediate Risk Non-Muscle Invasive Bladder Cancer

DrugNadofaragene Firadenovec

Ferring Pharmaceuticals

Phase 3

454

Santander, Barcelona, Córdoba, A Coruña, Granada, Alcorcón, Madrid, Bilbao

2024-10-01

By invitation

The Role of Executive Functioning in Complex Post-Traumatic Stress Disorder Among Female Survivors of Intimate Partner Violence

NCT06706882Neuropsychological Rehabilitation Program (VIRTRAEL/LUCCIDY), Standard Training (TAU)

Universidad de Granada

Not applicable

Granada

2024-10-01

Active, closed

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

NCT06190951Melanoma

DrugsFianlimab·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

151

Granada, Málaga, Palma, Badalona, Barcelona, El Palmar, Oviedo, Madrid

2024-09-18

Recruiting

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

NCT06140524Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 2

116

Granada, Terrassa, El Palmar, Gijón, Barcelona, Madrid, Murcia

2024-09-16

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

NCT06572384Lung Diseases, Interstitial

DrugBelimumab

GlaxoSmithKline

Phase 3

440

Pamplona Iruna, Barcelona, Córdoba, Granada, Madrid, Málaga, Santander, Seville

2024-09-11

By invitation

Task-oriented Training Intervention for Multiple Sclerosis Patients.

NCT07106255Multiple Sclerosis

Universidad de Granada

Not applicable

Granada

2024-09-01

Recruiting

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

NCT06435429Metastatic HER2-positive Breast Cancer

DrugsZanidatamab·Eribulin·Vinorelbine·Trastuzumab

Jazz Pharmaceuticals

Phase 3

550

A Coruña, Badajoz, Barcelona, Elche, Granada, Madrid, San Cristóbal de La Laguna, Seville

2024-08-13

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsSaruparib·Camizestrant·Exemestane·Anastrozole

AstraZeneca

Phase 3

788

A Coruña, Barcelona, Cáceres, Granada, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona

2024-08-01

By invitation

Liquid BiOpsy, Lung and Colon Cancer in AndaluciA

NCT06997458Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)

Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental

Observational

500

Granada

2024-08-01

Active, closed

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

NCT06440967Hot Flashes

DrugsFezolinetant·Tamoxifen

Astellas Pharma Global Development, Inc.

Phase 3

982

Barcelona, Elche, Girona, Granada, Jaén, León, Madrid, Majadahonda

2024-07-31

By invitation

Long-term Safety and Tolerability of BHV-7000

NCT06443463Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2

660

Badalona, L'Hospitalet de Llobregat, Pamplona, Vigo, Barcelona, Granada, Madrid, Málaga

2024-07-30

Active, closed

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

NCT06172127HER2-positive Breast Cancer

DrugsPhesgo·Trastuzumab deruxtecan

MedSIR

Phase 2

165

Seville, Alicante, Barcelona, Bilbao, Castellon, Córdoba, Granada, León

2024-07-22

Recruiting

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649Metastatic Colorectal Cancer

DrugsLumakras·Sotorasib·Bevacizumab-awwb·Panitumumab

Amgen

Phase 3

450

Córdoba, Granada, Málaga, Seville, Zaragoza, Santander, Burgos, Badalona

2024-07-17

Active, closed

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

NCT06161441Resectable Non-small Cell Lung Cancer

DrugsFianlimab·Cemiplimab·Paraplatin·Taxol

Regeneron Pharmaceuticals

Phase 2

195

Santiago de Compostela, Elche, Granada, Palma, Barcelona, Majadahonda, El Palmar, Pamplona

2024-07-16

Recruiting

Left Septal or Deep Septal Pacing to Prevent Pacing-induced Cardiomyopathy

NCT06474819Complete Heart Block, Second Degree Atrioventricular Block Möbitz Type II

Institut d'Investigació Biomèdica de Bellvitge

Not applicable

326

Barcelona, Castellon, Granada, L'Hospitalet de Llobregat, Valencia, Zaragoza

2024-07-12

Active, closed

A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

NCT06526182Dermatitis, Atopic, Eczema

DrugLebrikizumab

Almirall, S.A.

Phase 3

520

Alicante, Barcelona, Granada, Valencia

2024-07-03

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

NCT06015737Cutaneous Lupus Erythematosus

AstraZeneca

Phase 3

339

Barcelona, Castellon, Granada, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Salamanca

2024-06-29

Active, closed

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

NCT06425549Moderate to Severe Plaque Psoriasis

DrugsBimekizumab·Ustekinumab

UCB Biopharma SRL

Phase 3

176

Alicante, Esplugues de Llobregat, Granada

2024-06-25

Recruiting

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

NCT06389136Atopic Dermatitis

DrugsUpadacitinib·Dupilumab

AbbVie

Phase 3

200

Granada, Madrid, Valencia

2024-06-14

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

NCT06112314Advanced Melanoma

DrugsBrenetafusp·Relatlimab·Opdivo·Nivolumab

Immunocore Ltd

Phase 3

680

Santander, El Palmar, A Coruña, Barcelona, Córdoba, Granada, Las Palmas de Gran Canaria, Madrid

2024-06-05

Active, closed

T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases

NCT06048718Breast Cancer, Metastatic Breast Cancer

DrugTrastuzumab deruxtecan

MedSIR

Phase 2

Alicante, Barcelona, Bilbao, Córdoba, Granada, Madrid, Seville, Valencia

2024-06-05

Active, closed

A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

NCT06226571Acute Myeloid Leukemias

DrugRevumenib

Syndax Pharmaceuticals

Phase 1

Santander, Barcelona, Cáceres, Granada, Madrid, Salamanca, Seville, Valencia

2024-05-21

Recruiting

Hearing and Structure Preservation Via ECochG

NCT06268340Hearing Loss, Sensorineural, Severe-to-profound Hearing Loss

Advanced Bionics AG

Not applicable

102

Granada

2024-05-15

Active, closed

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

NCT05739942Newly Diagnosed and Recurrent Glioblastoma

DrugsGa-NeoB·Lu-NeoB

Novartis Pharmaceuticals

Phase 1

Granada, Badalona, L'Hospitalet de Llobregat, Madrid

2024-05-15

Active, closed

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06309966Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2/3

390

Badalona, L'Hospitalet de Llobregat, Pamplona, Vigo, Barcelona, Granada, Madrid, Málaga

2024-05-13

Active, closed

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

DrugNerandomilast

Boehringer Ingelheim

Phase 3

1,666

Alicante, Barcelona, Bilbao, El Palmar, Galdakao, Granada, L'Hospitalet de Llobregat, Madrid

2024-05-06

Recruiting

Transcranial Magnetic Stimulation and Inhibitory Control Training to Reduce Binge Eating: Brain and Behavioral Changes

NCT06649994Binge Eating, Inhibition, Psychological

Raquel Vilar López

Not applicable

150

Granada

2024-04-29

Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097Non-small Cell Lung Cancer

DrugsDato-DXd·Osimertinib

AstraZeneca

Phase 3

582

A Coruña, Barcelona, Granada, Madrid, Majadahonda, Valencia

2024-04-29

Recruiting

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

NCT05485961End Stage Kidney Disease

DrugClazakizumab

CSL Behring

Phase 2/3

3,110

Alcobendas, Barcelona, Córdoba, Girona, Granada, Guadalajara, Lleida, Madrid

2024-04-27

Active, closed

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

NCT06194448Lung Cancer

DrugsTagrisso·Osimertinib·Pemetrexed·Paclitaxel

AstraZeneca

Phase 2

Barcelona, Donostia / San Sebastian, Granada, Madrid

2024-04-21

Recruiting

Phase I-IIa, to Evaluate the Safety, Feasibility, and Efficacy of the Use of BIOCLEFT in the Treatment of Cleft Palate.

NCT06408337Cleft Lip and Palate

Elisa María Cubiles Montero de Espinosa

Phase 1/2

Granada

2024-04-17

Active, closed

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

NCT06004661Metastatic Castration-Resistant Prostate Cancer (mCRPC)

DrugsIlluccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 2

Granada, El Palmar

2024-04-04

Active, closed

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease

DrugPirfenidone

Avalyn Pharma Inc.

Phase 2

375

Granada, Barcelona, Santander, Madrid, Málaga, Oviedo, Seville, Cadiz

2024-04-03

Recruiting

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan

NCT06236269Breast Cancer Stage IV

DrugSacituzumab Govitecan

SOLTI Breast Cancer Research Group

Phase 2

Badalona, L'Hospitalet de Llobregat, Barcelona, Granada, Madrid, Reus, Seville, Valencia

2024-03-15

Recruiting

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

NCT05939414Oligometastatic Prostate Cancer (OMPC)

DrugsPiflufolastat·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

450

Granada, L'Hospitalet de Llobregat, Barcelona, El Palmar, Madrid, Seville, Valencia

2024-03-12

Recruiting

Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With STEMI

NCT06353594ST Elevation Myocardial Infarction

Hospital Universitario La Fe

Not applicable

1,272

Huelva, Valencia, A Coruña, Burgos, Castelló, Córdoba, Elche, Granada

2024-03-11

Active, closed

PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients

NCT06321757Coronary Artery Disease

Fundación EPIC

Observational

501

Albacete, Alicante, Barakaldo, Boadilla del Monte, Ciudad Real, Granada, Huelva, L'Hospitalet de Llobregat

2024-02-26

Recruiting

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

NCT06283966COPD (Chronic Obstructive Pulmonary Disease)

AstraZeneca

Phase 3

5,250

Alicante, Badia Del Vallès, Barakaldo, Barcelona, Castro Urdiales, Córdoba, Granada, Madrid

2024-02-21

Active, closed

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function

NCT05907096Delayed Graft Function

DrugEmpasiprubart

argenx

Phase 2

103

Badalona, Barcelona, Granada, L'Hospitalet de Llobregat, Valencia, Zaragoza

2024-02-17

By invitation

Intervention Study Focused on the Intestinal Microbiome to Evaluate the Impact of a Wild Thyme Extract (Thymus Serpyllum) Extract With Anti-inflammatory and Metabolic Properties Against Functional Gastrointestinal Disorders.

NCT06639126Functional Gastrointestinal Disorders

Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental

Not applicable

Granada

2024-02-01

By invitation

Impact of Nutritional Intervention With Probiotics and Prebiotics on Obesity.

NCT06722443Obesity and Overweight, Obesity, Morbid, Metabolic Syndrome

Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental

Not applicable

230

Granada

2024-02-01

Active, closed

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

NCT05955508Smoldering Multiple Myeloma (SMM)

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 2

Santiago de Compostela, Granada, Palma Mallorca, Badalona, Santander, Pozuelo de Alarcón, El Palmar, Pamplona

2024-01-30

Active, closed

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06212999Hidradenitis Suppurativa (HS)

DrugPovorcitinib

Incyte Corporation

Phase 3

617

Alicante, Badalona, Barcelona, Granada, Las Palmas de Gran Canaria, Madrid, Manises, Pontevedra

2024-01-30

Active, closed

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

NCT06107426Parkinson's Disease (PD)

AbbVie

Observational

427

Santiago de Compostela, Elche, Majadahonda, Granada, Madrid, Seville

2024-01-24

Active, closed

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

NCT06208150Multiple Myeloma

DrugsElotuzumab·Talquetamab·Velcade·Teclistamab

Janssen Research & Development, LLC

Phase 3

838

Asturias, Barcelona, Burgos, Cáceres, Donostia / San Sebastian, Granada, Lugo, Madrid

2024-01-22

Active, closed

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

NCT06143878Plaque Psoriasis

DrugsIcotrokinra·Deucravacitinib

Janssen Research & Development, LLC

Phase 3

774

Alicante, Barakaldo, Barcelona, Granada, L'Hospitalet de Llobregat, Madrid, Valencia

2024-01-17

Active, closed

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

NCT06079281Hypophosphatasia

DrugALXN1850

Alexion Pharmaceuticals, Inc.

Phase 3

124

Barcelona, Granada, Madrid, San Cristóbal de La Laguna, Santander, Vitoria-Gasteiz

2024-01-03

Recruiting

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

NCT05950945Breast Cancer

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 3

250

Barcelona, Donostia / San Sebastian, Granada, Las Palmas de Gran Canaria, Madrid, Majadahonda, Murcia, Pamplona

2023-12-30

Recruiting

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

NCT06149286Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

DrugsOdronextamab·Lenalidomide·Rituximab

Regeneron Pharmaceuticals

Phase 3

580

Santiago de Compostela, Palma, L'Hospitalet de Llobregat, Santander, Pozuelo de Alarcón, Oviedo, Barcelona, Granada

2023-12-28

Active, closed

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

NCT06118411Vitiligo

DrugUpadacitinib

AbbVie

Phase 3

614

Badalona, Getafe, Pozuelo de Alarcón, Granada, Madrid, Valencia, Zaragoza

2023-12-19

Recruiting

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

NCT06285318Relapsed/Refractory Multiple Myeloma (RRMM)

Janssen-Cilag Ltd.

Observational

900

Ávila, Granada, Madrid, Málaga, Valencia, Vigo

2023-12-18

Recruiting

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

NCT05512364ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer

DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

220

Alicante, Barakaldo, El Palmar, Girona, Granada, L'Hospitalet de Llobregat, Lleida, Madrid

2023-12-15

Active, closed

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

NCT05976243Chronic Inducible Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

362

Santiago, Granada, Barcelona, Alicante, Madrid, Valencia

2023-12-07

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06103864Breast Cancer

DrugsDato-DXd·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 3

625

Barcelona, Granada, Hospitalet deLlobregat, Madrid, Pamplona, Santander

2023-11-23

Active, closed

Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.

NCT06042478Chronic Spontaneous Urticaria

DrugsOmalizumab·Remibrutinib

Novartis Pharmaceuticals

Phase 3

470

Granada, Barcelona, Córdoba, Las Palmas GC, Valencia

2023-11-15

Active, closed

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT06136741Moderate to Severe Atopic Dermatitis

DrugRezpegaldesleukin

Nektar Therapeutics

Phase 2

396

Alicante, Córdoba, Granada, Seville, Zaragoza

2023-11-15

Active, closed

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

NCT06112379Breast Cancer

DrugsDato-DXd·Epirubicin·Xeloda·Olaparib

AstraZeneca

Phase 3

1,902

Barcelona, Granada, Hospitalet deLlobregat, Madrid, Santiago de Compostela, Seville, Zaragoza

2023-11-14

Recruiting

Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)

NCT05762211Transplant Complication

DrugPooled allogeneic fecal microbiotherapy

MaaT Pharma

Phase 2

387

Barcelona, Granada, Madrid, Majadahonda, Murcia, Pamplona, Salamanca, Santander

2023-10-31

Active, closed

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

NCT05949684Myelodysplastic Syndromes

DrugsEpoetin Alfa·Reblozyl·Luspatercept

Bristol-Myers Squibb

Phase 3

402

Barcelona, L'Hospitalet de Llobregat, Valencia, Granada, Madrid, Oviedo, Salamanca, Seville

2023-10-24

Active, closed

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

NCT06095102Plaque Psoriasis

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

311

Badalona, Barcelona, Esplugues de Llobregat, Granada, Madrid, Manises, Seville, Valencia

2023-10-12

Active, closed

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

NCT06045689Myelodysplastic Syndromes

DrugsReblozyl·Luspatercept

Bristol-Myers Squibb

Phase 3

106

L'Hospitalet de Llobregat, Barcelona, Granada, Madrid, Ourense, Salamanca, Valencia

2023-10-05

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic

DrugBelimumab

GlaxoSmithKline

Phase 2/3

300

Barcelona, Bilbao, Granada, Madrid, Seville, Valencia, VigoPontevedra

2023-09-13

Active, closed

Effectivenness and Implementation of an Intervention to Improve Primary Care Patient Safety

NCT05958108Patient Safety

Fundació d'investigació Sanitària de les Illes Balears

Phase 3

110

Granada, Palma de Mallorca, Barcelona, Madrid, Murcia, Salamanca, Pontevedra, Zaragoza

2023-09-01

Active, closed

Enlighten Study: The EV-ICD Post Approval Registry

NCT06048731Ventricular Arrhythmia, Tachycardia

Medtronic

Observational

1,000

A Coruña, Barcelona, Córdoba, Girona, Granada, Valencia

2023-09-01

Active, closed

Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

NCT05909397Breast Cancer

DrugsVepdegestrant·Letrozole

Pfizer

Phase 3

Badalona, Barcelona, Jaén, Málaga, Granada, Madrid

2023-08-09

Recruiting

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

NCT05855200Colonic Neoplasms, Neoplasms, Colon

DrugsCapeox·Dostarlimab·Folfox

GlaxoSmithKline

Phase 3

892

Badajoz, BaracaldoVizcaya, Barcelona, Córdoba, Donostia / San Sebastian, Elche Alicante, Granada, Jaén

2023-08-01

Recruiting

OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

NCT06068049Non-small Cell Lung Cancer

AstraZeneca

Observational

500

A Coruña, Alicante, Barcelona, C Rdoba, El Palmar, Girona, Granada, Jaén

2023-07-28

Active, closed

Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

NCT05968430Hypertension

Mineralys Therapeutics Inc.

Phase 3

1,076

Badajoz, Córdoba, Granada, Valencia

2023-07-14

Recruiting

PICAROS - Acalabrutinib RWE on 1L CLL in Spain

NCT05999877Chronic Lymphocytic Leukemia

AstraZeneca

Observational

315

Almería, Córdoba, Granada, Jaén, Marbella, Málaga, Seville, Zaragoza

2023-07-11

Active, closed

Evaluation of Marginal Bone Loss and Associated Factors Around Ziacom Dental Implants With Different Prosthetic Connection

NCT05859113Jaw, Edentulous, Partially

Universidad de Granada

Not applicable

Granada

2023-07-10

Recruiting

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

NCT05898399Advanced Solid Tumor, Metastatic Solid Tumor

DrugOlaparib

Artios Pharma Ltd

Phase 1/2

181

Granada, Valladolid, Barcelona, Cáceres, San Carlos, Cadiz, Madrid, Murcia

2023-06-30

Active, closed

Profile of Chronic Musculoskeletal Pain Patients Related to Treatment Adherence and Virtual Reality

NCT05925192Chronic Musculoskeletal Pain

Universidad de Granada

Observational

100

Granada

2023-06-30

Active, closed

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182Hidradenitis Suppurativa

DrugUpadacitinib

AbbVie

Phase 3

1,328

L'Hospitalet de Llobregat, Majadahonda, Manises, Barcelona, Granada, Madrid, Valencia

2023-06-21

Active, closed

A Real-life Study of the Use of Cabotegravir Plus Rilpivirine Long-acting in ART-experienced Pre-treated People With HIV

NCT06518408Human Immunodeficiency Virus

University Hospital Virgen de las Nieves

Observational

287

Granada, Logroño, Murcia, Cadiz, Córdoba, Jaén, Madrid, Palma de Mallorca

2023-06-01

Recruiting

GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma

NCT05992532Gaucher Disease, Acid SphingoMyelinase Deficiency

Fundación Española de Hematología y Hemoterapía

Observational

210

Vitoria-Gasteiz, Almería, Palma de Mallorca, Sabadell, Burgos, Valdepeñas, Girona, Granada

2023-05-30

Active, closed

PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin

NCT05810870Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer

DrugEribulin

MedSIR

Phase 2

Granada, Seville, Donostia / San Sebastian, Santander, A Coruña, Torrejón de Ardoz, Vigo, Barcelona

2023-05-24

Recruiting

Effectiveness and Implementation of a Digital Intervention for Pediatric Chronic Pain Co-designed With Patients

NCT05917626Chronic Pain

University of Malaga

Not applicable

195

Almería, Barcelona, Granada, Madrid, Cartagena, Málaga

2023-05-05

Recruiting

Usefulness of PET-CT for Invasive Fungal Infection

NCT05688592Invasive Fungal Infections

Puerta de Hierro University Hospital

Observational

224

Majadahonda, Barcelona, Granada, Madrid, Málaga, Murcia, Oviedo, Salamanca

2023-04-27

Active, closed

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

NCT05611931Endometrial Cancer

DrugSelinexor

Karyopharm Therapeutics Inc

Phase 3

257

Donostia / San Sebastian, Zaragoza, Badalona, Barcelona, Córdoba, Girona, Granada, Madrid

2023-04-18

Active, closed

A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

NCT05723562Neoplasms, Rectal

DrugDostarlimab

GlaxoSmithKline

Phase 2

154

Barcelona, Granada, Madrid, Santander, Valencia

2023-04-03

Active, closed

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

14,012

Ferrol, Santiago, Santiago Compostela, Elche, Granada, Huelva, Marbella, Málaga

2023-03-09

Active, closed

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

NCT05526755Stage II-IIIB Non-small Cell Lung Carcinoma

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 2

188

Badalona, Barcelona, Bilbao, Granada, L'Hospitalet de Llobregat, Madrid, Seville, Valencia

2023-03-06

Active, closed

Profile of COVID-19 Patients Related to Fatigue

NCT05731817COVID-19

Universidad de Granada

Observational

398

Granada

2023-02-15

Recruiting

The ENERGYCO Study

NCT06414668Energy Expenditure, Physical Activity, Behavior, Body Composition

Universidad de Granada

Not applicable

300

Granada

2023-02-01

Active, closed

Metabolome and Microbiome Impact on Acute GVHD in Recipients of Hematopoietic Transplant

NCT05186857Graft-versus-host Disease

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Observational

Santander, Córdoba, Granada, Madrid, Málaga, Salamanca, Seville, Valencia

2023-01-23

Active, closed

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

NCT05608291Melanoma

DrugsFianlimab·Cemiplimab·Keytruda·Pembrolizumab

Regeneron Pharmaceuticals

Phase 3

1,564

Badalona, Santander, Barcelona, Oviedo, Granada, Lugo, Madrid, Seville

2023-01-16

Active, closed

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

NCT05552976Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Carfilzomib·Dexamethasone

Bristol-Myers Squibb

Phase 3

606

Badalona, Barcelona, L'Hospitalet Del Llobregat, Madrid, Majadahonda, San Cristóbal de La Laguna, Valencia, Granada

2023-01-10

Recruiting

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

NCT05306041HER2-positive Breast Cancer

DrugsPhesgo·Inavolisib

GBG Forschungs GmbH

Phase 2

170

Barcelona, Granada, Lleida, Madrid, Murcia, Palma de Mallorca, Santander, Seville

2023-01-02

Active, closed

Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

NCT05024773Bladder Carcinoma in Situ (CIS)

Fidia Farmaceutici s.p.a.

Phase 3

130

Barcelona, Valencia, Bilbao, Córdoba, Granada, Madrid, Málaga

2022-12-29

Recruiting

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

NCT05712200Atrial Fibrillation (AF)

DrugAbelacimab

Anthos Therapeutics, Inc.

Phase 3

2,500

A Coruña, Almería, Barcelona, Cabra, Granada, Jaén, León, Madrid

2022-12-27

Active, closed

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

NCT05469737Myelodysplastic Syndromes

DrugAzacitidine

Bristol-Myers Squibb

Phase 2/3

230

Valencia, Granada, Madrid, Ourense, Oviedo, Salamanca

2022-12-14

Active, closed

Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia

NCT05325593Primary Immune Thrombocytopenia

DrugsRomiplostim·Dexamethasone

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase 3

129

Barcelona, Burgos, A Coruña, Granada, Madrid, Murcia, Málaga, Salamanca

2022-12-02

Recruiting

The Impact of Radiotherapy on Oligometastatic Cancer

NCT05933876Metastasis, Metastatic Breast Cancer, Metastatic Prostate Cancer, Metastatic Colorectal Cancer

Institut Investigacio Sanitaria Pere Virgili

Observational

2,000

Albacete, Barcelona, Granada, Lleida, Madrid, Seville, Reus, Valencia

2022-12-01

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222Multiple Myeloma

DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,590

Badalona, Barcelona, Granada, Jerez de la Frontera, Madrid, Palma de Mallorca, Pozuelo de Alarcón, Salamanca

2022-10-25

Active, closed

A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp

NCT05387525Keratosis, Actinic

DrugDiclofenac Sodium

Almirall, S.A.

Phase 4

447

Barcelona, Granada, Madrid, Salamanca, Seville, Valencia, Zaragoza

2022-10-24

Active, closed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes

Bayer

Phase 3

474

Santiago de Compostela, Aravaca, Barcelona, Granada, Madrid, Seville, Valencia

2022-10-14

Active, closed

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

NCT05556512Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

15,374

A Coruña, Almería, Alzira, Barcelona, Bilbao, Ferrol, Granada, León

2022-10-11

Recruiting

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

NCT05334368Hypereosinophilic Syndrome

DrugDepemokimab

GlaxoSmithKline

Phase 3

109

Barcelona, Granada, Madrid, Pozuelo de AlarcOn Madr, Salamanca, Valencia, Zaragoza

2022-09-06

By invitation

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

NCT04905693Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis

DrugTreprostinil

United Therapeutics

Phase 3

1,850

Santiago de Compostela, Palma de Mallorca, L'Hospitalet de Llobregat, Málaga, Oviedo, Barcelona, Granada, Madrid

2022-09-06

Active, closed

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

NCT05296798Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Phesgo·Pertuzumab·Trastuzumab

Hoffmann-La Roche

Phase 3

922

Sant Andreu de la Barca, Santiago de Compostela, San Cristóbal de La Laguna, Barcelona, Granada, Huelva, Madrid, Málaga

2022-07-18

Active, closed

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

NCT05263934Eosinophilic Granulomatosis With Polyangiitis

DrugsDepemokimab·Mepolizumab

GlaxoSmithKline

Phase 3

163

Barcelona, Granada, Pamplona, Zaragoza

2022-07-14

Recruiting

Photobiomodulation Therapy Plus M-health in Head and Neck Cancer Patients: LAXER Study

NCT05106608Head and Neck Cancer, Head and Neck Neoplasms, Xerostomia

Universidad de Granada

Not applicable

Granada

2022-07-13

Active, closed

The Left Bundle Cardiac Resynchronization Therapy Trial

NCT05434962Left Bundle-Branch Block, Heart Failure, Impaired Left Ventricular Function

Óscar Cano Pérez

Not applicable

176

Alicante, L'Hospitalet de Llobregat, Granada, Huelva, Madrid, Majadahonda, Murcia, Valencia

2022-06-27

Recruiting

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

NCT05462106Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease

AC Immune SA

Phase 1/2

304

Barcelona, Granada, Madrid, Santander, Valencia

2022-06-21

Recruiting

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

NCT05429632Adult Acute Myeloid Leukemia

Priothera SAS

Phase 3

366

Barcelona, Granada, Las Palmas de Gran Canaria, Madrid, Salamanca, Valencia

2022-06-16

Active, closed

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

NCT05374512Breast Cancer

DrugsEribulin·Dato-DXd·Nab-paclitaxel·Capecitabine

AstraZeneca

Phase 3

644

Barcelona, Granada, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Santiago de Compostela, Seville

2022-05-16

Active, closed

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

NCT05109728Glioblastoma

Drugs[177Lu]Lu-DOTA-TATE·[68Ga]Ga-DOTA-TATE·Lutathera

Novartis Pharmaceuticals

Phase 1

Granada, Barcelona, Madrid

2022-05-10

Active, closed

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

NCT05296746Breast Cancer Stage II

DrugRibociclib

SOLTI Breast Cancer Research Group

Phase 2

1,100

Palma de Mallorca, Badalona, L'Hospitalet de Llobregat, Barcelona, Granada, León, Madrid, Salamanca

2022-05-03

Active, closed

MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients

NCT04769895Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD

MaaT Pharma

Phase 3

Barcelona, El Palmar, Granada, Madrid, Murcia, Pamplona, Salamanca, Santander

2022-03-25

Active, closed

Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used as a Bridging Stent With Branched and Fenestrated Endografts in the Treatment of Aortic Aneurysms Involving the Renal-Mesenteric Arteries

NCT05143138Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm

W.L.Gore & Associates

Observational

259

Granada, Madrid

2022-03-23

Recruiting

Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

NCT05398094Non-small Cell Lung Cancer Stage III, KRAS P.G12C

DrugSotorasib

Fundación GECP

Phase 2

Alicante, Badalona, Barcelona, Bilbao, Girona, Granada, Jaén, A Coruña

2022-03-21

Active, closed

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

DrugsRuxience·Truxima·Zanubrutinib·Obinutuzumab

BeOne Medicines

Phase 3

799

Badalona, Burgos, Cadiz, Granada, L'Hospitalet de Llobregat, León, Madrid, Majadahonda

2022-03-10

Active, closed

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

NCT05202509Atherosclerotic Cardiovascular Disease

DrugObicetrapib

NewAmsterdam Pharma

Phase 3

9,541

A Coruña, Alicante, Almería, Barcelona, Córdoba, Granada, Madrid, Málaga

2022-02-07

Active, closed

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT05221840Non-Small Cell Lung Cancer

DrugsMonalizumab·Oleclumab·Durvalumab

AstraZeneca

Phase 3

1,051

Barcelona, Granada, Madrid, Santiago de Compostela, Valencia

2022-02-07

Recruiting

REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs

NCT05223413Anthracycline-induced Cardiac Toxicity, Lymphoma

Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

Not applicable

608

Alcalá de Henares, Barcelona, Granada, Madrid, Salamanca, Seville, Valladolid

2022-01-18

Active, closed

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

NCT05139602Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 2

210

Manises, Barcelona, Granada, Madrid

2021-12-28

Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT05160584Relapsed/Refractory Multiple Myeloma

Janssen Pharmaceutica N.V., Belgium

Observational

300

Barcelona, Gijón, Granada, Jerez de la Frontera, León, Madrid, Palma, Pamplona

2021-11-18

Active, closed

A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis

NCT05081557Atopic Dermatitis

AbbVie

Observational

873

Badalona, Barcelona, L'Hospitalet de Llobregat, Terrassa, Granada, Huelva, Jaén, Logroño

2021-11-17

Recruiting

Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis

NCT04924868Acute Pancreatitis Due to Gallstones

DrugUrsodeoxycholic Acid

Hospital General Universitario de Alicante

Phase 3

332

Santiago de Compostela, Alicante, Elche, Barcelona, L'Hospitalet de Llobregat, Sabadell, Santander, Granada

2021-11-10

Active, closed

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

DrugsBosutinib·Asciminib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 3

405

Granada, El Palmar, Pamplona, Barcelona, Madrid

2021-10-06

Active, closed

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

NCT04975308Breast Neoplasms, Neoplasm Metastasis

DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

874

Barcelona, Cáceres, Lleida, Madrid, San Cristóbal de La Laguna, Valencia, Granada, Seville

2021-10-04

Active, closed

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

NCT05049798Arthritis, Psoriatic

DrugsIL-17i·Tremfya·Guselkumab

Janssen Pharmaceutica N.V., Belgium

Observational

1,314

A Coruña, Algeciras / Cadiz, Barcelona, Bilbao, Córdoba, Granada, Madrid, Oviedo

2021-08-25

Active, closed

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755Neoplasms, Breast

DrugNiraparib

GlaxoSmithKline

Phase 3

Barcelona, Cáceres, Córdoba, Granada, Madrid, Málaga, Santiago de Compostela, Valencia

2021-06-28

Recruiting

Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System

NCT04798261Pulmonary Embolism

Penumbra Inc.

Observational

1,500

Granada, Zaragoza

2021-06-25

Active, closed

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

NCT04739761Breast Cancer

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 3

506

Barcelona, Bilbao (Vizcaya), Granada, Madrid, Salamanca, Santander, Santiago de Compostela-Coruña, Seville

2021-06-22

Active, closed

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT04895241Lupus Erythematosus, Systemic

DrugLitifilimab

Biogen

Phase 3

548

Santander, Valladolid, Barcelona, Granada, Seville, Valencia

2021-05-25

Recruiting

Spanish Series of Patients Treated With the Radionuclide Lutetium177

NCT04949282Neuroendocrine Tumors, Intestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

DrugsLutetium [177Lu] oxodotreotide/dotatate·Lutathera

Sociedad Española de Medicina Nuclear e Imagen Molecular

Observational

5,000

Santiago de Compostela, Granada, Palma de Mallorca, L'Hospitalet de Llobregat, Getafe, Majadahonda, El Palmar, Pamplona

2021-05-10

Active, closed

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Abemaciclib·Ribociclib·Palbociclib

AstraZeneca

Phase 3

893

Barcelona, Granada, Lleida, Madrid, Málaga, Pamplona, Santiago de Compostela

2021-05-10

Active, closed

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

NCT04873362Breast Cancer

DrugsTrastuzumab emtansine·Herceptin·Tecentriq·Trastuzumab

Hoffmann-La Roche

Phase 3

1,188

Elche, Badalona, Sabadell, Jerez de la Frontera, Vigo, San Cristóbal de La Laguna, Bilbao, Granada

2021-05-04

Active, closed

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

NCT04576156Myelofibrosis

DrugImetelstat Sodium

Geron Corporation

Phase 3

327

Alicante, Badalona, Las Palmas de Gran Canaria, Cáceres, Granada, Madrid, Málaga, Zaragoza

2021-04-12

Active, closed

Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer

NCT04759248Breast Cancer

DrugsVinorelbine·Trastuzumab·Atezolizumab

SOLTI Breast Cancer Research Group

Phase 2

Granada, Barcelona, L'Hospitalet de Llobregat, Santa Cruz de Tenerife, A Coruña, Alicante, Cáceres, León

2021-03-15

Recruiting

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

NCT04710576Chronic Graft-versus-host-disease

DrugAxatilimab

Syndax Pharmaceuticals

Phase 2

296

Seville, Barcelona, Donostia / San Sebastian, Granada, Madrid, Majadahonda, Salamanca, Santander

2021-03-04

Active, closed

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

NCT04717414Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis

DrugLuspatercept

Celgene

Phase 3

313

Barcelona, Granada, Las Palmas de Gran Canaria, Madrid, Palma de Mallorca, Salamanca, Santiago de Compostela, Seville

2021-02-25

Active, closed

Goat Infant Formula Feeding and Eczema (the GIraFFE Study)

NCT04599946Dermatitis, Atopic, Eczema, Infantile, Infant Development, Child Development

Dairy Goat Co-operative (N.Z.) Limited

Not applicable

2,132

Almería, Granada, Madrid, Reus, Tarragona, Valencia, Zaragoza

2021-01-08

Recruiting

Natural History of Clostridioides Difficile Infection

NCT04801862Clostridium Difficile Infection, Health Care Associated Infection, Nosocomial Infection

Hospital Universitario de Valme

Observational

750

Alicante, Orihuela, Villajoyosa, Puerto Real, Granada, Huelva, Málaga, Valencia

2021-01-01

Recruiting

Preventing Chemotherapy-induced Peripheral Neuropathy Using PRESIONA Exercise Program

NCT04652609Breast Neoplasm

Universidad de Granada

Not applicable

Granada

2021-01-01

Active, closed

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

NCT04640623Urinary Bladder Neoplasms

DrugsTAR-200·Cetrelimab

Janssen Research & Development, LLC

Phase 2

220

A Coruña, Badalona, Barcelona, Cadiz, Granada, Jerez de la Frontera, Madrid, Málaga

2020-12-18

Active, closed

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

NCT04658862Urinary Bladder Neoplasms

DrugsTAR-200·Cetrelimab·Gemcitabine·Cisplatin

Janssen Research & Development, LLC

Phase 3

518

A Coruña, Badalona, Barcelona, Granada, Jerez de la Frontera, Madrid, Sabadell, Santander

2020-12-07

Active, closed

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

NCT04512235AL Amyloidosis

DrugsAnselamimab·Cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)

Alexion Pharmaceuticals, Inc.

Phase 3

281

Barcelona, Gijón, Granada, Madrid, Majadahonda, Pamplona, Salamanca, Seville

2020-11-03

Active, closed

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

NCT04468984Myelofibrosis (MF)

DrugsNavitoclax·Ruxolitinib

AbbVie

Phase 3

330

A Coruña, Santiago de Compostela, Badalona, Las Palmas de Gran Canaria, Oviedo, Barcelona, Granada, Madrid

2020-08-31

Active, closed

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

NCT04421963Ovarian Cancer, Breast Cancer

DrugOlaparib

AstraZeneca

Phase 3

185

Badalona, Barcelona, Córdoba, Donostia / San Sebastian, Granada, Madrid, Pamplona, Valencia

2020-08-04

Active, closed

Personalized Therapy Study - HFRS (TriageHF) Post Approval Study

NCT04489225Heart Failure

Medtronic

Observational

2,200

A Coruña, Granada, Madrid, Salamanca, Santa Cruz de Tenerife, Santiago, Valladolid

2020-08-01

Recruiting

OP2C : Prialt® Observatory in Clinical Practice

NCT04321408Refractory Pain

DrugZiconotide

Institut Cancerologie de l'Ouest

Observational

300

Cadiz, Cartagena, Granada, Ourense, Seville, Valencia

2020-07-10

Active, closed

Lifestyles and Breast Cancer

NCT04174391Malignant Tumor of Breast

University of Navarra

Not applicable

766

Santander, Granada, Jaén, Pamplona

2020-05-29

Recruiting

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

NCT04256317Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia

DrugsVenclexta·Azacitidine·Venetoclax

Taiho Oncology, Inc.

Phase 2/3

316

Badalona, L'Hospitalet de Llobregat, Pamplona, Oviedo, Barcelona, Cáceres, Girona, Granada

2020-05-21

Active, closed

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

NCT03937154Chemotherapy-induced Thrombocytopenia

DrugsNplate·Romiplostim

Amgen

Phase 3

145

Granada, Seville, Salamanca, Barcelona, Ourense, Fuenlabrada, Castellon, Madrid

2020-02-26

Active, closed

Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC

NCT03965468Non-small Cell Lung Cancer, Stage IV, Oligometastasis

DrugsTremelimumab·Durvalumab·Paclitaxel·Carboplatin

ETOP IBCSG Partners Foundation

Phase 2

Barcelona, Granada, Madrid, Valencia

2019-11-19

Active, closed

Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

NCT04041310Solid Tumor, Adult

DrugsKeytruda·Pembrolizumab

Nouscom SRL

Phase 1/2

115

A Coruña, Barcelona, Córdoba, Granada, Madrid, Pamplona, Salamanca, Santander

2019-10-21

Active, closed

Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer

NCT04186013Bladder Cancer

DrugsTecentriq·Atezolizumab

Spanish Oncology Genito-Urinary Group

Phase 2

Manresa, Sabadell, Reus, Granada, Lugo, Madrid, Ourense, Oviedo

2019-09-18

Recruiting

Spine Bone Cements Outcomes - Post Market Follow-up

NCT06367582Vertebral Fracture, Compression Fracture, Osteoporotic Fractures

Teknimed

Observational

500

Barcelona, Granada, Murcia, Terrassa, Zafra

2019-09-04

Recruiting

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

NCT04043494Lymphoblastic Lymphoma, Childhood

DrugsVindesine·Thioguanine·PEG-Asparaginase·Ifosfamide

University Hospital Muenster

Phase 3

683

Alicante, Almería, Badajoz, Barakaldo, Barcelona, Donostia / San Sebastian, Esplugues de Llobregat, Granada

2019-08-23

Active, closed

Childhood Obesity Risk Assessment Longitudinal Study

NCT06317883Child Obesity

Consorcio Centro de Investigación Biomédica en Red (CIBER)

Observational

1,508

Santiago de Compostela, Pamplona, Barcelona, Córdoba, Granada, Tarragona, Valencia, Zaragoza

2019-05-27

Recruiting

Safety of IBD Drugs During Pregnancy and Breastfeeding: Mothers and Babies' Outcomes (DUMBO Registry)

NCT03894228Inflammatory Bowel Diseases, Pregnancy

Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

Observational

1,750

Santiago de Compostela, Córdoba, Granada, Huelva, Málaga, Seville, Huesca, Zaragoza

2019-05-21

Active, closed

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT03827798Hidradenitis Suppurativa

DrugsArumakimig·Ianalumab·Remibrutinib

Novartis Pharmaceuticals

Phase 2

248

Granada, Sabadell, Manises, Barcelona, Las Palmas GC, Valencia

2019-02-27

Active, closed

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

NCT03796962Focal Epilepsy

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 2

325

Seville, Badalona, Pamplona, Barcelona, Granada, Madrid, Málaga, Valencia

2019-01-30

Active, closed

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

NCT03682536Myelodysplastic Syndromes

DrugsEpoetin Alfa·Luspatercept

Celgene

Phase 3

363

Barcelona, Granada, Madrid, Málaga, Murcia, Ourense, Oviedo, Palma de Mallorca

2019-01-02

Active, closed

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334Early Breast Cancer

DrugRibociclib

Novartis Pharmaceuticals

Phase 3

5,101

Elche, Granada, Huelva, Jaén, Vitoria-Gasteiz, Badalona, L'Hospitalet de Llobregat, Manresa

2018-12-07

Active, closed

Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

NCT03595592Invasive Breast Cancer

DrugsPerjeta·Herceptin·Tecentriq·Pertuzumab

Fondazione Michelangelo

Phase 3

650

A Coruña, Alcoy, Alicante, Badajoz, Barcelona, Bilbao, Cáceres, Granada

2018-09-07

Active, closed

Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain

NCT03605771Melanoma Stage Iv, Melanoma Stage Iii, Advanced Cancer

Grupo Español Multidisciplinar de Melanoma

Observational

400

Alcoy, Granada, Málaga, Barcelona, Sabadell, Vitoria-Gasteiz, Santander, Burgos

2018-08-07

Active, closed

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

NCT03390504Urothelial Cancer

DrugsVinflunine·Erdafitinib·Docetaxel·Pembrolizumab

Janssen Research & Development, LLC

Phase 3

629

Badajoz, Badalona, Barcelona, Cáceres, Córdoba, Granada, Jaén, Las Palmas de Gran Canaria

2018-03-23

Active, closed

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

NCT03260023HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma

DrugAvelumab

Transgene

Phase 1/2

143

Badalona, Granada, Madrid, Málaga, Valencia

2017-09-01

Active, closed

Personalized Therapy Study - Attain Stability Quad Post-Approval Study

NCT04024943Heart Failure

Medtronic

Observational

1,092

A Coruña, Granada, Madrid, Salamanca, Santa Cruz de Tenerife, Santiago de Compostela, Valladolid

2017-08-21

Active, closed

Prospective Registry for Patients Undergoing Surgery for Male Stress Urinary Incontinence

NCT02757274Urinary Incontinence, Stress

European Association of Urology Research Foundation

Observational

1,054

Barcelona, Granada, Madrid, Murcia, San Cristóbal de La Laguna, Valencia

2017-02-22

Active, closed

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520HIV Infections

DrugsCabotegravir (CAB)·Rilpivirine (RPV)·Rilpivirine·Cabotegravir

ViiV Healthcare

Phase 3

631

A Coruña, Barcelona, Bilbao, Elche Alicante, Ferrol, Granada, La Laguna Santa Cruz, Madrid

2016-10-27

Recruiting

Product Surveillance Registry

NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders

Medtronic

Observational

100,000

A Coruña, Córdoba, Elche, Girona, Granada, L'Hospitalet de Llobregat, Madrid, Málaga

2012-01

Recruiting

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

NCT00825929HIV Infections

Radboud University Medical Center

Observational

176

Badalona, Granada

2009-02

Active, closed

Psoriasis Longitudinal Assessment and Registry

NCT00508547Psoriasis

Janssen Scientific Affairs, LLC

Observational

20,167

Alcalá de Henares, Bilbao, Granada, Madrid, Majadahonda, Murcia, Salamanca, Santiago de Compostela

2007-06-21

Recruiting

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

NCT00271180Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia

Medtronic

Observational

20,000

A Coruña, Barcelona, Córdoba, Girona, Granada, Madrid, Palma de Mallorca, Salamanca

1983-01

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/granada

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 310 of those studies with a site in Granada.

How many clinical trials are recruiting in Granada?

155 of the 310 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 16 have not yet opened recruitment, 128 are active but closed to new participants, and 11 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Granada), 310 studies
Phase	Studies	Recruiting	Share
Phase 3	123	56	39.7%
Phase 2	63	33	20.3%
Observational	49	26	15.8%
Not applicable	46	24	14.8%
Phase 1/2	10	6	3.2%
Phase 2/3	8	4	2.6%
Phase 1	5	1	1.6%
Phase 4	5	4	1.6%
Early Phase 1	1	1	0.3%

Most active sponsors

Lead sponsors with the most studies (Granada)
Lead sponsor	Studies	Recruiting
Universidad de Granada	28	11
AstraZeneca	22	13
Novartis Pharmaceuticals	15	3
Janssen Research & Development, LLC	9	2
AbbVie	8	2
Eli Lilly and Company	8	6
GlaxoSmithKline	7	4
Incyte Corporation	7	1
Pfizer	7	4
Hoffmann-La Roche	6	4

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.